PEPG Earnings

PEPG reported its earnings on 2025-11-06, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.63 by 0%. The stock experienced a 9.74% price change on the earnings day and a 21.85% change over the next five days, reflecting market reactions to the results.

Following PEPG's earnings announcement on 2025-11-06, the stock price moved by 9.74% on the day of the release. Over the subsequent five days, it saw a 21.85% change. Historically, PEPG's stock price tends to shift by an average of 7% in the 10 days leading up to earnings and 2.84% in the 10 days following, providing insight into potential market.

For , analysts estimate PEPG's annual revenue to reach undefined, while the EPS is projected at -0.37. These estimates reflect recent revisions, with revenue estimates revised upward by 0.74% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PEPG's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised upward by 0.74%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PEPG's stock price typically moves by 7% in the 10 days before its earnings and 2.84% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.37 and revenue of undefined.

The earnings call reveals financial challenges, with cash reserves declining and significant net losses due to increased R&D expenses. While there is optimism about dystrophin levels in trials, uncertainties exist regarding patient recruitment and trial timelines. The Q&A section highlights operational and scientific risks, with management providing vague responses on key timelines and regulatory endpoints. Despite potential positive outcomes in therapy development, the financial strain and lack of clear guidance create a negative sentiment. The absence of a market cap further complicates the assessment, leading to a prediction of a negative stock price movement.